Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify...
Source: prnewswire.com